C-peptide in diabetes mellitus treated with insulin. A 3-year epidemiological study on the island of Falster, Denmark

Diabetes Res. 1986 Nov;3(9):475-8.

Abstract

In a 3 yr prospective epidemiological study of 227 insulin-treated diabetics the clinical value of fasting C-peptide measurements for discriminating between insulin dependence and non-insulin dependence was assessed. A significant difference (p less than 0.01) in fasting C-peptide secretion was found between diabetics with an early onset age (less than 30 yr) and a late onset age (greater than or equal to 30 yr). Among diabetics with a late onset age (n = 124) 45% were classified as non-insulin dependent according to fasting C-peptide levels (greater than 0.40 pmol/ml) and characterized by overweight. Diabetics with C-peptide concentrations less than 20 pmol/ml were characterized by an early onset of diabetes mellitus (less than 30 yr), the duration of diabetes mellitus (greater than 5 yr), slight deviation from ideal weight, development of insulin antibodies and high daily insulin dosage. Among the 57 diabetics with a C-peptide level greater than 0.40 pmol/ml 31 accepted and could maintain good metabolic control in a period of 3 yr after change from treatment with insulin to treatment with oral hypoglycaemic agent and diet or diet regime alone. It is concluded that measurement of fasting C-peptide is of additional clinical importance for the choice of treatment of diabetics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • C-Peptide / blood*
  • Diabetes Mellitus, Type 1 / blood*
  • Diabetes Mellitus, Type 1 / classification
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / classification
  • Diabetes Mellitus, Type 2 / drug therapy
  • Female
  • Glycated Hemoglobin A / analysis
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use*
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • C-Peptide
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin